Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Insulin (ORMD-0801) for NASH in Type 2 Diabetes
NCT04616014Phase 2Completed
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ORMD-0801 in Nonalcoholic steatohepatitis (NASH), sponsored by Oramed Pharmaceuticals Inc. Primary endpoint: Number of Participants With Treatment-related Adverse Events. Started Mar 2021; status: completed.
02
Drugs
ORMD-0801
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04616014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616014.